Focus: Antares Therapeutics is a public biotechnology company headquartered in South San Francisco specializing in small molecule technologies across endocrinology, immunology, oncology, neurology, and gastroenterology. The company is publicly traded and operates a focused portfolio anchored by migraine and hormone replacement therapies.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
A mid-cap biotech bet on Novartis-backed oncology discovery with moderate stability from marketed migraine and hormone products, but execution risk is high given revenue concentration and patent-cliff exposure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship NDA product in peak commercial phase; 5-HT 1B/1D receptor agonist; LOE 2036 provides 10-year revenue runway.
Help build intelligence for Antares Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Antares Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic ANDA product post-LOE; represents commoditized sumatriptan market entry.
Generic ANDA product post-LOE; represents commoditized sumatriptan market entry.
Generic ANDA product post-LOE; represents commoditized sumatriptan market entry.
Generic ANDA product post-LOE; represents commoditized sumatriptan market entry.
Generic ANDA product in pre-launch phase; pending commercial entry into migraine market.
Generic ANDA product post-LOE; represents commoditized sumatriptan market entry.
NDA product with LOE approaching November 2026; auto-injector formulation; near-term patent cliff risk.
NDA product in peak lifecycle; testosterone enanthate auto-injector for hormone replacement; LOE 2038 provides 12-year runway.
5 discontinued, 2 duplicate formulations not shown
Antares & Novartis: A Major Oncology Drug Collaboration - Healthcare Digital
Antares & Novartis: A Major Oncology Drug Collaboration Healthcare Digital
Antares lands $1.9bn Novartis deal for cancer drug discovery - BioXconomy
Antares lands $1.9bn Novartis deal for cancer drug discovery BioXconomy
Novartis oncology partnership with Antares, shares trade near analyst targets - Ad-hoc-news.de
Novartis oncology partnership with Antares, shares trade near analyst targets Ad-hoc-news.de
Antares Therapeutics Enters Agreement with Novartis to Develop First-in-Class Cancer Therapies - IndiaMedToday
Antares Therapeutics Enters Agreement with Novartis to Develop First-in-Class Cancer Therapies IndiaMedToday
Scorpion team lands $1.9B Novartis deal with new biotech - The Business Journals
Scorpion team lands $1.9B Novartis deal with new biotech The Business Journals
Novartis pays Antares $105M to illuminate undruggable cancer targets - Fierce Biotech
Novartis pays Antares $105M to illuminate undruggable cancer targets Fierce Biotech
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+2 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo